Review of the New Delayed‐Release Oral Tablet and Intravenous Dosage Forms of Posaconazole

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 2, 2015-02 ,pp. : 208-219

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis

By Herbrecht Raoul   Rajagopalan Srinivasan   Danna Robert   Papadopoulos George  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2457-2464

Informa Healthcare

Access to resources Recommend Favorite

Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands

By Jansen J. P.   Meis J. F.   Blijlevens N. M.   van't Wout J. W.  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1535-1546

Informa Healthcare

Access to resources Recommend Favorite

Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet

By Garikipati Vandana   Toops Dana S.   Fang Qi  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1869-1876

Informa Healthcare

Access to resources Recommend Favorite

Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis

By  

MYCOSES (ELECTRONIC), Vol. 58, Iss. 7, 2015-07 ,pp. : 432-436

John Wiley & Sons Inc

Access to resources Recommend Favorite